Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Sanofi names its API spin-off Euroapi
by Rick Mullin
January 23, 2021
| A version of this story appeared in
Volume 99, Issue 3
Sanofi has picked EuroAPI as the name of its active pharmaceutical ingredient (API) manufacturing unit and Karl Rotthier, former CEO of Centrient Pharmaceuticals, as CEO of the business. Positioning EuroAPI as a “made-in-Europe” pharmaceutical services venture, the French drugmaker claims that the unit will be the world’s largest small-molecule API producer and second-largest general API contractor. Sanofi expects EuroAPI to have $1.2 billion in sales in 2022, when it plans a stock offering of the firm.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X